Healthcare Services

A key trend shaping the Radiopharmaceutical Theranostics Market involves the Advancements In Theranostics For Targeted Cancer Treatment By Major Companies In Radiopharmaceutical Market

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Radiopharmaceutical Theranostics Market Between 2026 And 2030?

The radiopharmaceutical theranostics market size has experienced rapid growth in recent years. It is forecast to increase from $3.27 billion in 2025 to $3.76 billion in 2026, at a compound annual growth rate (CAGR) of 15.0%. The expansion observed in the historic period is attributable to several factors, including the widening of nuclear medicine applications, an increase in cancer incidence rates, advancements in radioisotope production techniques, greater integration of diagnostic imaging, and the early adoption of theranostic treatment models.

The radiopharmaceutical theranostics market is projected to experience swift expansion over the coming years. This market is set to reach $6.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.3%. This projected growth is primarily driven by factors such as increasing investments in precision oncology, a heightened demand for tailored radiopharmaceutical treatments, the expansion of clinical trials for new isotopes, stronger partnerships between diagnostic and therapeutic sectors, and continuous advancements in isotope supply chains. Key trends anticipated during this period encompass the escalating development of targeted theranostic radiopharmaceuticals, an increased application of PET-based personalized therapies, the broader embrace of alpha and beta emitters in cancer treatment, the expansion of cyclotron-based isotope manufacturing, and a sharpened focus on precision oncology applications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp

What Major Drivers Are Influencing Demand In The Radiopharmaceutical Theranostics Market?

The increasing occurrence of cancer is projected to fuel the expansion of the radiopharmaceutical theranostics market moving ahead. Cancer is defined as a complex condition characterized by the abnormal proliferation of cells, capable of invading and disseminating throughout the body. Radiopharmaceutical theranostics offers assistance in combating cancer through tailored and personalized treatment strategies. For example, estimates from the US-based voluntary cancer health organization, the American Cancer Society, indicate that in the US in 2023, approximately 1.9 million new cancer diagnoses are anticipated, alongside an estimated 609,820 cancer-related fatalities. Furthermore, it is projected that 88% of those diagnosed will be from the age group of 50 years or older. Consequently, the increasing prevalence of cancer is a key factor propelling the development of the radiopharmaceutical theranostics market.

Which Market Segments Are Examined In The Radiopharmaceutical Theranostics Market Study?

The radiopharmaceutical theranostics market covered in this report is segmented –

1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers

2) By Source: Nuclear Reactors, Cyclotrons

3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes

4) By Indication: Oncology, Cardiology, Neurology, Other Indications

5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals

2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals

3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET Tracers

What Key Trends Are Influencing The Development Of The Radiopharmaceutical Theranostics Market?

Major companies operating in the radiopharmaceutical theranostics market are concentrating their efforts on developing theranostic solutions aimed at combating cancer. Theranostic approaches are also being explored for managing rare diseases, with a focus on delivering targeted therapies and diagnostic tools for patients with limited treatment options, such as various types of cancer. For instance, in November 2023, GE HealthCare Technologies Inc., a US-based medical technology company, launched its theranostics solutions tailored for cancer. Theranostics represents an innovative area of precision medicine that utilizes therapeutic agents in conjunction with imaging technology to identify and precisely target cancer cells for destruction.

Who Are The Primary Competitors In The Radiopharmaceutical Theranostics Market?

Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

Read the full radiopharmaceutical theranostics market report here:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Radiopharmaceutical Theranostics Market?

North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Radiopharmaceutical Theranostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11951&type=smp

Browse Through More Reports Similar to the Global Radiopharmaceutical Theranostics Market 2026, By The Business Research Company

Radiology As A Service Global Market Report

https://www.thebusinessresearchcompany.com/report/radiology-as-a-service-global-market-report

Radiology Information Systems Global Market Report

https://www.thebusinessresearchcompany.com/report/radiology-information-systems-global-market-report

Oncologists Global Market Report

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795